Difference between revisions of "Afuresertib (GSK-2110183)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Oral AKT inhibitor ==Preliminary results== # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen ...") |
Warner-admin (talk | contribs) m (Warner-admin moved page Afuresertib (GSK2110183) to Afuresertib (GSK-2110183) without leaving a redirect) |
||
| (16 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=642287 NCI Drug Dictionary]: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. | |
| − | ==Preliminary | + | ==Preliminary data== |
| − | # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows | + | ===[[Multiple myeloma]]=== |
| − | favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [http://www.bloodjournal.org/content/124/14/2190 link to original article] [ | + | # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [http://www.bloodjournal.org/content/124/14/2190 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25075128/ PubMed] |
| − | [[Category: | + | ==Also known as== |
| − | [[Category: | + | *'''Code name:''' GSK-2110183 |
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | |||
| + | [[Category:AKT1 inhibitors]] | ||
| + | |||
| + | [[Category:Multiple myeloma medications (investigational)]] | ||
| + | |||
| + | [[Category:Investigational drugs]] | ||
Revision as of 22:02, 25 July 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
Preliminary data
Multiple myeloma
- Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article PubMed
Also known as
- Code name: GSK-2110183